Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers

[1]  K. Wohlfarth,et al.  Neurophysiological Double-Blind Trial of a Botulinum Neurotoxin Type A Free of Complexing Proteins , 2007, Clinical neuropharmacology.

[2]  W. Jost,et al.  Botulinum toxin: clinical use. , 2006, Parkinsonism & related disorders.

[3]  D. Dressler,et al.  Pharmacology of botulinum toxin: differences between type A preparations , 2006, European journal of neurology.

[4]  A. Marchetti,et al.  Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study , 2005, Movement disorders : official journal of the Movement Disorder Society.

[5]  K. Bihari.  Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm , 2005, Current medical research and opinion.

[6]  J. Jankovic,et al.  Botulinum toxin in clinical practice , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[7]  C. Sampaio,et al.  Clinical comparability of marketed formulations of botulinum toxin , 2004, Movement disorders : official journal of the Movement Disorder Society.

[8]  K. Wohlfarth,et al.  Pharmacokinetic properties of different formulations of botulinum neurotoxin type A , 2004, Movement disorders : official journal of the Movement Disorder Society.

[9]  D. Sesardic,et al.  Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin. , 2003, Biologicals : journal of the International Association of Biological Standardization.

[10]  W. Poewe.  Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia , 2002, Journal of neurology, neurosurgery, and psychiatry.

[11]  C. Sampaio,et al.  DYSBOT: A single‐blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1 , 1997, Movement disorders : official journal of the Movement Disorder Society.

[12]  P. Roggenkämper,et al.  Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm , 1997, Graefe's Archive for Clinical and Experimental Ophthalmology.

[13]  K. Wohlfarth,et al.  Botulinum A toxins: units versus units , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[14]  P. Hambleton,et al.  Potency equivalence of botulinum toxin preparations. , 1994, Journal of the Royal Society of Medicine.

[15]  McCormack Mp,et al.  Medico-legal reports. , 1993 .

[16]  E J Schantz,et al.  Properties and use of botulinum toxin and other microbial neurotoxins in medicine. , 1992, Microbiological reviews.

[17]  J. Nyborg,et al.  Mechanisms of Tax Regulation of Human T Cell Leukemia Virus Type I Gene Expression. , 1995, Journal of biomedical science.

[18]  I. Lorentz,et al.  Botulinum toxin: dangerous terminology errors. , 1994, Journal of the Royal Society of Medicine.

[19]  木村 淳.  Electrodiagnosis in diseases of nerve and muscle : principles and practice , 1983 .